Isoniazid- and rifampicin-induced thrombocytopenia

Treatment of tuberculosis has many side effects. Thrombocytopenia is a serious side effect of such treatment and occurs mostly due to rifampicin (RIF). There are very few reported cases of thrombocytopenia due to isoniazid (INH). An 18-year-old female patient was diagnosed with smear-positive pulmon...

Full description

Saved in:
Bibliographic Details
Published in:Multidisciplinary respiratory medicine 2013-02, Vol.8 (1), p.13-13, Article 13
Main Authors: Yakar, Fatih, Yildiz, Namşan, Yakar, Aysun, Kılıçaslan, Zeki
Format: Article
Language:English
Subjects:
Care and treatment
Case Report
Health aspects
Isoniazid
Rifampin
Thrombocytopenia
Tuberculosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c521t-63b8c849be8f01cb61c2d9cc0f1dddc71b2c2f66a136863cd7b68f32b4f3b5e43
cites cdi_FETCH-LOGICAL-c521t-63b8c849be8f01cb61c2d9cc0f1dddc71b2c2f66a136863cd7b68f32b4f3b5e43
container_end_page 13
container_issue 1
container_start_page 13
container_title Multidisciplinary respiratory medicine
container_volume 8
creator Yakar, Fatih
Yildiz, Namşan
Yakar, Aysun
Kılıçaslan, Zeki
description Treatment of tuberculosis has many side effects. Thrombocytopenia is a serious side effect of such treatment and occurs mostly due to rifampicin (RIF). There are very few reported cases of thrombocytopenia due to isoniazid (INH). An 18-year-old female patient was diagnosed with smear-positive pulmonary tuberculosis. A four-drug regimen [INH, RIF, ethambutol (EMB), and pyrazinamide (PZA)] was given. After the development of thrombocytopenia, the drug treatment was stopped, and a thrombocyte suspension was given until a normal thrombocyte count was obtained. After several start-stop trials, first INH and then RIF were identified as the possible causes of thrombocytopenia and were removed from the regimen. The patient was treated with EMB, streptomycin, PZA, and moxifloxacin with no further development of thrombocytopenia. The current case shows that antituberculosis drugs other than RIF and PZA may be responsible for the development of thrombocytopenia.
doi_str_mv 10.1186/2049-6958-8-13
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3660205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534834672</galeid><sourcerecordid>A534834672</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-63b8c849be8f01cb61c2d9cc0f1dddc71b2c2f66a136863cd7b68f32b4f3b5e43</originalsourceid><addsrcrecordid>eNptkc1LAzEQxYMoWmqvHqUgeFvN12bTiyDFLxC8KHgLySRxI7tJ2WyF-te7S7UomDlkmPm9R8JD6ITgC0KkuKSYLwqxKGUhC8L20GQ32EcTIqkc-9cjNMv5HQ9HlISV_BAdUcaxkLyaIPqQUwz6M9hirqOdd8HrdhUgxCJEuwZn533dpdYk2PRp5Qb2GB143WQ3-76n6OX25nl5Xzw-3T0srx8LKCnpC8GMBMkXxkmPCRhBgNoFAPbEWgsVMRSoF0ITJqRgYCsjpGfUcM9M6Tiboqut72ptWmfBxb7TjVp1odXdRiUd1N9NDLV6Sx-KCYEpLgeDs63Bm26cCtGnAYM2ZFDXJeOScVHRgbr4hxrKujZAis6HYf5HcP5LUDvd9HVOzboPKeZ_naFLOXfO795OsBoDVGNeasxLSUXYIDj9_eMd_hMX-wKxeZUa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Isoniazid- and rifampicin-induced thrombocytopenia</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Yakar, Fatih ; Yildiz, Namşan ; Yakar, Aysun ; Kılıçaslan, Zeki</creator><creatorcontrib>Yakar, Fatih ; Yildiz, Namşan ; Yakar, Aysun ; Kılıçaslan, Zeki</creatorcontrib><description>Treatment of tuberculosis has many side effects. Thrombocytopenia is a serious side effect of such treatment and occurs mostly due to rifampicin (RIF). There are very few reported cases of thrombocytopenia due to isoniazid (INH). An 18-year-old female patient was diagnosed with smear-positive pulmonary tuberculosis. A four-drug regimen [INH, RIF, ethambutol (EMB), and pyrazinamide (PZA)] was given. After the development of thrombocytopenia, the drug treatment was stopped, and a thrombocyte suspension was given until a normal thrombocyte count was obtained. After several start-stop trials, first INH and then RIF were identified as the possible causes of thrombocytopenia and were removed from the regimen. The patient was treated with EMB, streptomycin, PZA, and moxifloxacin with no further development of thrombocytopenia. The current case shows that antituberculosis drugs other than RIF and PZA may be responsible for the development of thrombocytopenia.</description><identifier>ISSN: 1828-695X</identifier><identifier>ISSN: 2049-6958</identifier><identifier>EISSN: 2049-6958</identifier><identifier>DOI: 10.1186/2049-6958-8-13</identifier><identifier>PMID: 23406847</identifier><language>eng</language><publisher>Italy: BioMed Central Ltd</publisher><subject>Care and treatment ; Case Report ; Health aspects ; Isoniazid ; Rifampin ; Thrombocytopenia ; Tuberculosis</subject><ispartof>Multidisciplinary respiratory medicine, 2013-02, Vol.8 (1), p.13-13, Article 13</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>Copyright © 2013 Yakar et al.; licensee BioMed Central Ltd. 2013 Yakar et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-63b8c849be8f01cb61c2d9cc0f1dddc71b2c2f66a136863cd7b68f32b4f3b5e43</citedby><cites>FETCH-LOGICAL-c521t-63b8c849be8f01cb61c2d9cc0f1dddc71b2c2f66a136863cd7b68f32b4f3b5e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660205/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660205/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23406847$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yakar, Fatih</creatorcontrib><creatorcontrib>Yildiz, Namşan</creatorcontrib><creatorcontrib>Yakar, Aysun</creatorcontrib><creatorcontrib>Kılıçaslan, Zeki</creatorcontrib><title>Isoniazid- and rifampicin-induced thrombocytopenia</title><title>Multidisciplinary respiratory medicine</title><addtitle>Multidiscip Respir Med</addtitle><description>Treatment of tuberculosis has many side effects. Thrombocytopenia is a serious side effect of such treatment and occurs mostly due to rifampicin (RIF). There are very few reported cases of thrombocytopenia due to isoniazid (INH). An 18-year-old female patient was diagnosed with smear-positive pulmonary tuberculosis. A four-drug regimen [INH, RIF, ethambutol (EMB), and pyrazinamide (PZA)] was given. After the development of thrombocytopenia, the drug treatment was stopped, and a thrombocyte suspension was given until a normal thrombocyte count was obtained. After several start-stop trials, first INH and then RIF were identified as the possible causes of thrombocytopenia and were removed from the regimen. The patient was treated with EMB, streptomycin, PZA, and moxifloxacin with no further development of thrombocytopenia. The current case shows that antituberculosis drugs other than RIF and PZA may be responsible for the development of thrombocytopenia.</description><subject>Care and treatment</subject><subject>Case Report</subject><subject>Health aspects</subject><subject>Isoniazid</subject><subject>Rifampin</subject><subject>Thrombocytopenia</subject><subject>Tuberculosis</subject><issn>1828-695X</issn><issn>2049-6958</issn><issn>2049-6958</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNptkc1LAzEQxYMoWmqvHqUgeFvN12bTiyDFLxC8KHgLySRxI7tJ2WyF-te7S7UomDlkmPm9R8JD6ITgC0KkuKSYLwqxKGUhC8L20GQ32EcTIqkc-9cjNMv5HQ9HlISV_BAdUcaxkLyaIPqQUwz6M9hirqOdd8HrdhUgxCJEuwZn533dpdYk2PRp5Qb2GB143WQ3-76n6OX25nl5Xzw-3T0srx8LKCnpC8GMBMkXxkmPCRhBgNoFAPbEWgsVMRSoF0ITJqRgYCsjpGfUcM9M6Tiboqut72ptWmfBxb7TjVp1odXdRiUd1N9NDLV6Sx-KCYEpLgeDs63Bm26cCtGnAYM2ZFDXJeOScVHRgbr4hxrKujZAis6HYf5HcP5LUDvd9HVOzboPKeZ_naFLOXfO795OsBoDVGNeasxLSUXYIDj9_eMd_hMX-wKxeZUa</recordid><startdate>20130213</startdate><enddate>20130213</enddate><creator>Yakar, Fatih</creator><creator>Yildiz, Namşan</creator><creator>Yakar, Aysun</creator><creator>Kılıçaslan, Zeki</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20130213</creationdate><title>Isoniazid- and rifampicin-induced thrombocytopenia</title><author>Yakar, Fatih ; Yildiz, Namşan ; Yakar, Aysun ; Kılıçaslan, Zeki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-63b8c849be8f01cb61c2d9cc0f1dddc71b2c2f66a136863cd7b68f32b4f3b5e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Care and treatment</topic><topic>Case Report</topic><topic>Health aspects</topic><topic>Isoniazid</topic><topic>Rifampin</topic><topic>Thrombocytopenia</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yakar, Fatih</creatorcontrib><creatorcontrib>Yildiz, Namşan</creatorcontrib><creatorcontrib>Yakar, Aysun</creatorcontrib><creatorcontrib>Kılıçaslan, Zeki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Multidisciplinary respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yakar, Fatih</au><au>Yildiz, Namşan</au><au>Yakar, Aysun</au><au>Kılıçaslan, Zeki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isoniazid- and rifampicin-induced thrombocytopenia</atitle><jtitle>Multidisciplinary respiratory medicine</jtitle><addtitle>Multidiscip Respir Med</addtitle><date>2013-02-13</date><risdate>2013</risdate><volume>8</volume><issue>1</issue><spage>13</spage><epage>13</epage><pages>13-13</pages><artnum>13</artnum><issn>1828-695X</issn><issn>2049-6958</issn><eissn>2049-6958</eissn><abstract>Treatment of tuberculosis has many side effects. Thrombocytopenia is a serious side effect of such treatment and occurs mostly due to rifampicin (RIF). There are very few reported cases of thrombocytopenia due to isoniazid (INH). An 18-year-old female patient was diagnosed with smear-positive pulmonary tuberculosis. A four-drug regimen [INH, RIF, ethambutol (EMB), and pyrazinamide (PZA)] was given. After the development of thrombocytopenia, the drug treatment was stopped, and a thrombocyte suspension was given until a normal thrombocyte count was obtained. After several start-stop trials, first INH and then RIF were identified as the possible causes of thrombocytopenia and were removed from the regimen. The patient was treated with EMB, streptomycin, PZA, and moxifloxacin with no further development of thrombocytopenia. The current case shows that antituberculosis drugs other than RIF and PZA may be responsible for the development of thrombocytopenia.</abstract><cop>Italy</cop><pub>BioMed Central Ltd</pub><pmid>23406847</pmid><doi>10.1186/2049-6958-8-13</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1828-695X
ispartof Multidisciplinary respiratory medicine, 2013-02, Vol.8 (1), p.13-13, Article 13
issn 1828-695X
2049-6958
2049-6958
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3660205
source Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Care and treatment
Case Report
Health aspects
Isoniazid
Rifampin
Thrombocytopenia
Tuberculosis
title Isoniazid- and rifampicin-induced thrombocytopenia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A06%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isoniazid-%20and%20rifampicin-induced%20thrombocytopenia&rft.jtitle=Multidisciplinary%20respiratory%20medicine&rft.au=Yakar,%20Fatih&rft.date=2013-02-13&rft.volume=8&rft.issue=1&rft.spage=13&rft.epage=13&rft.pages=13-13&rft.artnum=13&rft.issn=1828-695X&rft.eissn=2049-6958&rft_id=info:doi/10.1186/2049-6958-8-13&rft_dat=%3Cgale_pubme%3EA534834672%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c521t-63b8c849be8f01cb61c2d9cc0f1dddc71b2c2f66a136863cd7b68f32b4f3b5e43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/23406847&rft_galeid=A534834672&rfr_iscdi=true